Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christos Chouaid

Showing results (171-180 of 210) with videos related to

Pageof 21
Sort By:
Cancers|December 23, 2022
Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP CohortsChristos Chouaid, Michael Thomas, Didier Debieuvre, et al.
Future Oncology (London, England)|February 25, 2025
Advancing real-world research in thoracic malignancies: learnings from the international I-O Optimise initiativeSøren Paaske Johnsen, Paul Baas, Jens Benn Sørensen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 18, 2013
Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III studyOlivier Bylicki, Céline Ferlay, Christos Chouaid, et al.
Lung Cancer (Amsterdam, Netherlands)|November 2, 2022
Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapyGrégoire Justeau, Eric Huchot, Yannick Simonneau, et al.
Chest|March 11, 2026
Association of sleep-related hypoxemia with survival in patients with non-small cell lung cancer - the NEOSAS-GFPC study groupGrégoire Justeau, Laurent Greillier, Florent Vinas, et al.
Lung Cancer (Amsterdam, Netherlands)|September 13, 2014
Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01)Christos Chouaid, Cecile Dujon, Pascal Do, et al.
The European Respiratory Journal|October 28, 2017
Association between lung cancer somatic mutations and occupational exposure in never-smokersChristophe Paris, Pascal Do, Bénédicte Mastroianni, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2017
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung CancerEnriqueta Felip, Fabrice Barlesi, Benjamin Besse, et al.
Lung Cancer (Amsterdam, Netherlands)|August 25, 2022
Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and GermanyFrank Griesinger, Maurice Pérol, Nicolas Girard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2013
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectivesJulien Mazières, Solange Peters, Benoit Lepage, et al.
Pageof 21

Showing results (171-180 of 210) with videos related to

Sort By:
Pageof 21
Cancers|December 23, 2022
Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP CohortsChristos Chouaid, Michael Thomas, Didier Debieuvre, et al.
Future Oncology (London, England)|February 25, 2025
Advancing real-world research in thoracic malignancies: learnings from the international I-O Optimise initiativeSøren Paaske Johnsen, Paul Baas, Jens Benn Sørensen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 18, 2013
Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III studyOlivier Bylicki, Céline Ferlay, Christos Chouaid, et al.
Lung Cancer (Amsterdam, Netherlands)|November 2, 2022
Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapyGrégoire Justeau, Eric Huchot, Yannick Simonneau, et al.
Chest|March 11, 2026
Association of sleep-related hypoxemia with survival in patients with non-small cell lung cancer - the NEOSAS-GFPC study groupGrégoire Justeau, Laurent Greillier, Florent Vinas, et al.
Lung Cancer (Amsterdam, Netherlands)|September 13, 2014
Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01)Christos Chouaid, Cecile Dujon, Pascal Do, et al.
The European Respiratory Journal|October 28, 2017
Association between lung cancer somatic mutations and occupational exposure in never-smokersChristophe Paris, Pascal Do, Bénédicte Mastroianni, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2017
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung CancerEnriqueta Felip, Fabrice Barlesi, Benjamin Besse, et al.
Lung Cancer (Amsterdam, Netherlands)|August 25, 2022
Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and GermanyFrank Griesinger, Maurice Pérol, Nicolas Girard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2013
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectivesJulien Mazières, Solange Peters, Benoit Lepage, et al.
Pageof 21